TickerFacts.

Tevogen Inc. (TVGN): Operating Cash Flow

Annual figures by period end, from SEC filings.

-$12.33M
Year ended 2025-12-31
-$11.57M
Trailing 12 months to 2026-06-30
2022-12-31: -$215.4K2023-12-31: -$8.17M2024-12-31: -$12.00M2025-12-31: -$12.33M-$12.33M
2022-12-31 Operating Cash Flow (USD) 2025-12-31
Period endedOperating Cash FlowChange YoYSource filing
2025-12-31-$12.33Mn/m2026-03-31, From 2025-01-01
2024-12-31-$12.00Mn/m2026-03-31, From 2024-01-01
2023-12-31-$8.17Mn/m2025-04-02, From 2023-01-01
2022-12-31-$215.4Kn/a2024-04-29, From 2022-01-01

Operating Cash Flow at similar companies

Companies with the same SEC industry code (Biological Products, (No Diagnostic Substances)), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedOperating Cash FlowChange YoY
Tevogen Inc. (TVGN)2025-12-31-$12.33Mn/m
Eloxx Pharmaceuticals, Inc. (ELOX)2025-12-31-$6.33Mn/m
Cero Therapeutics Holdings, Inc. (CERO)2025-12-31-$16.10Mn/a
BioCardia, Inc. (BCDA)2025-12-31-$7.44Mn/m
AIM ImmunoTech Inc. (AIM)2025-12-31-$10.96Mn/m
Exozymes Inc. (EXOZ)2025-12-31-$6.50Mn/m
Estrella Immunopharma, Inc. (ESLA)2025-12-31-$1.79Mn/a
Silexion Therapeutics Corp (SLXN)2025-12-31-$10.82Mn/m
VivoSim Labs, Inc. (VIVS)2026-03-31-$10.83Mn/m

Compare TVGN, ELOX, CERO, BCDA side by side · Screen every company in Biological Products, (No Diagnostic Substances) ↗